London, UK – October 26, 2026 – AstraZeneca, the UK-Swedish biopharmaceutical giant, has recently unveiled significant clinical trial readouts for key assets within its robust oncology portfolio, painting a picture of both remarkable progress and notable challenges. The company has shared late-stage data for its blockbuster antibody-drug conjugate (ADC) Enhertu, its highly successful epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso, and its selective estrogen receptor degrader (SERD) Etcamah. While Enhertu and Tagrisso have demonstrated substantial advancements, particularly in lung cancer, Etcamah’s journey in breast cancer has encountered a significant hurdle.
The latest disclosures, largely presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, highlight the dynamic nature of drug development and the complex landscape of cancer treatment. These results are crucial for shaping future treatment paradigms and underscore AstraZeneca’s continued commitment to advancing cancer care across various tumor types.
Enhertu Establishes New Standard of Care in Frontline HER2-Mutant NSCLC
AstraZeneca, in collaboration with Daiichi Sankyo, has reported a landmark Phase III success for Enhertu (trastuzumab deruxtecan) in the DESTINY-Lung04 study (NCT05048797). This trial investigated Enhertu’s efficacy as a frontline treatment for patients with HER2-mutant, non-squamous non-small cell lung cancer (NSCLC), a patient population historically associated with poorer prognoses. The results position Enhertu as a potential new standard of care (SoC) in this setting, offering a significant improvement over the current chemotherapy and immunotherapy backbone.
Chronology of the DESTINY-Lung04 Trial:
The DESTINY-Lung04 study meticulously compared Enhertu against the established SoC, which typically comprises chemotherapy in combination with MSD’s blockbuster immunotherapy, Keytruda (pembrolizumab). Patients were enrolled and treated, with researchers closely monitoring progression-free survival (PFS) as the primary endpoint. The trial’s design aimed to rigorously assess Enhertu’s ability to not only halt disease progression but also to improve overall survival and quality of life for patients with this specific genetic alteration.
Supporting Data and Key Findings:
The data presented at WCLC 2026 revealed a compelling efficacy profile for Enhertu. The drug demonstrated a statistically significant improvement in PFS, reducing the risk of disease progression or death by an impressive 37% compared to the SoC. This translated into a median PFS of 14.3 months for patients treated with Enhertu, a six-month increase over the control arm.
Beyond the primary endpoint, Enhertu also showed favorable PFS trends across critical patient subgroups. Notably, this included patients with brain metastases, a common and challenging complication of advanced lung cancer, and those with liver metastases, which often indicate a more aggressive disease. Furthermore, patients with specific HER2 mutations that are often linked to poor outcomes also experienced notable benefits.
The objective response rate (ORR), a measure of how many patients achieve a significant reduction in tumor size, was also substantially higher in the Enhertu arm, reaching 70% compared to 44.5% in the SoC group. The safety profile of Enhertu in this study remained consistent with previously observed data, reassuring clinicians about its tolerability in a frontline setting.
Official Responses and Expert Commentary:
Susan Galbraith, Executive Vice President of Oncology and Haematology at AstraZeneca, expressed enthusiasm for the DESTINY-Lung04 findings. She stated that the trial’s success "could highlight the drug’s potential in newly diagnosed metastatic patients," emphasizing that this initial treatment period "has the greatest opportunity to improve outcomes." This sentiment is echoed by oncologists who recognize the critical need for more effective options in the frontline setting, especially for rare but aggressive mutations like HER2.
Implications for Treatment and Market:
HER2 mutations are relatively uncommon in NSCLC, occurring in approximately 2%-4% of cases. However, these mutations are often associated with a poor prognosis, with limited long-term survival rates. The current approval of Enhertu by US regulators for various HER2-expressing tumors, including NSCLC, breast, and gastric cancers, provides a foundation for this new indication.
GlobalData, the parent company of Clinical Trials Arena, forecasts significant market potential for Enhertu, projecting sales to approach $13 billion in 2032. This new frontline indication for HER2-mutant NSCLC is expected to further bolster these projections and solidify Enhertu’s position as a leading oncology therapy. This development marks a pivotal moment in the treatment of HER2-mutant NSCLC, offering a much-needed therapeutic advancement for a patient population with limited options.
Tagrisso Continues to Impress with Sustained Eight-Year Overall Survival Benefit in EGFR-Mutated NSCLC
AstraZeneca’s success story in lung cancer was further amplified by positive long-term outcome data from the Phase III ADAURA study (NCT02511106) for Tagrisso (osimertinib). Tagrisso, an EGFR TKI, has been a cornerstone of treatment for EGFR-mutated NSCLC, and the latest findings presented at WCLC 2026 reinforce its profound and durable impact on patient survival.
Chronology of the ADAURA Study and Follow-up:
The ADAURA trial initially investigated the efficacy of Tagrisso in the adjuvant setting, meaning it was given to patients after surgery to remove their EGFR-mutated NSCLC. The study compared Tagrisso to a placebo, with the option for patients to receive chemotherapy at the discretion of their physician. The long-term follow-up presented at WCLC 2026 provides an unprecedented look at the sustained benefits of Tagrisso over an eight-year period.
Supporting Data and Key Findings:
At the eight-year mark, Tagrisso demonstrated a remarkable 47% reduction in the risk of death compared to placebo across all predefined subgroups. This sustained overall survival (OS) benefit underscores Tagrisso’s transformative potential in maintaining long-term disease control and improving the lives of patients with EGFR-mutated NSCLC.
Roy Herbst, principal investigator of the ADAURA study, described the results as "particularly impressive," attributing this to the high rates of crossover to Tagrisso by patients in the placebo arm following disease recurrence. This highlights the compelling evidence for Tagrisso’s efficacy that even prompted patients to switch therapies.
Complementary real-world evidence (RWE) also debuted at WCLC 2026, further reinforcing the importance of completing Tagrisso’s full three-year treatment course. The RWE indicated that patients who discontinued treatment early were more than twice as likely to experience disease recurrence or death, emphasizing the critical need for adherence to the prescribed regimen.
Official Responses and Expert Commentary:
Herbst’s statement, "This durable OS benefit reinforces the importance of prioritising EGFR testing at diagnosis so as many patients as possible can benefit from this transformative therapy," emphasizes the critical role of early and accurate molecular profiling in identifying eligible patients. This highlights a key takeaway for clinical practice: proactive testing for EGFR mutations is paramount to unlocking the full potential of therapies like Tagrisso.
Implications for Treatment and Market:
The prevalence of EGFR mutations in NSCLC varies geographically, ranging from 10%-15% in European and American populations to 30%-40% in Asian patients. Currently, AstraZeneca asserts that Tagrisso is the only targeted therapy to demonstrate efficacy across all stages of EGFR-mutated NSCLC.
GlobalData forecasts Tagrisso’s sales to peak in 2031 at just over $9.3 billion, a testament to its established efficacy and broad patient applicability. The continued demonstration of long-term survival benefits solidifies Tagrisso’s position as a foundational therapy for EGFR-mutated NSCLC and reinforces its significant contribution to improving patient outcomes in this disease.
Etcamah Misses Primary Endpoint in Late-Stage Breast Cancer Trial, But Focus Remains on Future Opportunities
In stark contrast to the successes of Enhertu and Tagrisso, AstraZeneca’s breast cancer therapy, Etcamah (camizestrant), has faced a significant setback. Data from the late-stage SERENA-4 study (NCT04711252) revealed that Etcamah failed to meet its primary endpoint, casting a shadow over its immediate prospects in treatment-naïve patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
Chronology of the SERENA-4 Study:
The SERENA-4 trial was designed to evaluate the efficacy of Etcamah, a selective estrogen receptor degrader (SERD), when combined with Pfizer’s CDK 4/6 inhibitor Ibrance (palbociclib). This investigational combination was pitted against the current standard of care in this setting: Ibrance in combination with the hormone therapy anastrozole. The study aimed to determine if the addition of Etcamah would significantly improve progression-free survival (PFS) compared to the existing regimen.
Supporting Data and Key Findings:
Despite a numerical improvement in PFS observed in the Etcamah arm, the difference did not reach statistical significance compared to the control group. This outcome represents a disappointing result for the development of Etcamah in this specific patient population.
Official Responses and Expert Commentary:
Susan Galbraith acknowledged the disappointment surrounding the SERENA-4 outcome. She stated, "Whilst we are disappointed by the SERENA-4 outcome, it sharpens our focus on maximising the number of patients who can benefit from Etcamah today based on SERENA-6 and reinforces the importance of ESR1 testing for patients on first-line therapy." This statement signals a strategic shift, emphasizing the importance of ESR1 mutations, which are often found in patients whose breast cancer has progressed on endocrine therapy, and highlighting the ongoing research in other Etcamah trials.
Implications for Treatment and Market:
Despite the setback in SERENA-4, AstraZeneca remains committed to the development of Etcamah. Galbraith highlighted early breast cancer as an "important opportunity" for the drug. The company is forging ahead with the Phase III CAMBRIA program, a duo of trials investigating Etcamah’s potential in both intermediate-risk and high-risk patients following surgical removal of their tumors. These trials are exploring Etcamah’s efficacy as a monotherapy, in combination regimens, and as a sequential treatment after CDK 4/6 inhibitors.
GlobalData analysts forecast Etcamah to achieve over $4 billion in sales during 2032. This projection likely incorporates the potential of Etcamah in other indications and treatment lines, suggesting that the SERENA-4 outcome, while significant, may not entirely derail its commercial trajectory. The focus now shifts to demonstrating Etcamah’s value in different therapeutic contexts and patient populations where its mechanism of action may prove more impactful. This experience underscores the inherent risks and complexities of drug development, particularly in highly competitive fields like breast cancer treatment.
About the Author
